Josef Pfeilschifter Selected Research

NVP 231

12/2014	The ceramide kinase inhibitor NVP-231 inhibits breast and lung cancer cell proliferation by inducing M phase arrest and subsequent cell death.
1/2014	Ceramide kinase contributes to proliferation but not to prostaglandin E2 formation in renal mesangial cells and fibroblasts.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Josef Pfeilschifter Research Topics

Disease

50	Inflammation (Inflammations) 02/2020 - 03/2000
29	Wounds and Injuries (Trauma) 09/2021 - 03/2002
24	Neoplasms (Cancer) 04/2022 - 08/2002
16	Carcinoma (Carcinomatosis) 04/2022 - 08/2002
16	Fibrosis (Cirrhosis) 04/2022 - 01/2007
15	Infections 01/2018 - 08/2002
12	Sepsis (Septicemia) 01/2018 - 08/2003
11	Glomerulonephritis 01/2017 - 03/2000
10	Stroke (Strokes) 08/2020 - 11/2009
8	Kidney Diseases (Kidney Disease) 01/2021 - 03/2002
8	Hepatocellular Carcinoma (Hepatoma) 03/2020 - 01/2015
7	Carcinogenesis 03/2017 - 04/2004
6	Liver Diseases (Liver Disease) 11/2019 - 07/2014
6	Endotoxemia 01/2016 - 03/2000
6	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2016 - 01/2003
5	Hypoxia (Hypoxemia) 05/2022 - 10/2005
5	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 03/2009
5	Ischemic Stroke 08/2020 - 01/2011
5	Breast Neoplasms (Breast Cancer) 02/2020 - 12/2005
5	Atherosclerosis 01/2019 - 10/2002
4	Melanoma (Melanoma, Malignant) 04/2022 - 03/2010
4	Ureteral Obstruction 01/2021 - 01/2007
4	Reperfusion Injury 10/2020 - 02/2004
4	Colorectal Neoplasms (Colorectal Cancer) 10/2020 - 08/2002
4	Liver Cirrhosis (Hepatic Cirrhosis) 01/2019 - 09/2012
4	Insulin Resistance 07/2017 - 03/2006
4	Relapsing-Remitting Multiple Sclerosis 01/2016 - 01/2013
4	Virus Diseases (Viral Diseases) 07/2014 - 06/2008
4	Neoplasm Metastasis (Metastasis) 11/2011 - 01/2003
3	Multiple Sclerosis 01/2021 - 03/2011
3	Chronic Renal Insufficiency 01/2021 - 01/2014
3	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2021 - 10/2014
3	Type 2 Diabetes Mellitus (MODY) 01/2019 - 10/2008
3	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2018 - 03/2011
3	Autoimmune Diseases (Autoimmune Disease) 10/2014 - 08/2003
3	Ventilator-Induced Lung Injury 06/2013 - 04/2008
3	Kidney Neoplasms (Kidney Cancer) 02/2013 - 03/2011
3	Rheumatoid Arthritis 01/2013 - 01/2003
3	Brain Ischemia (Cerebral Ischemia) 09/2011 - 11/2009
3	Diabetic Nephropathies (Diabetic Nephropathy) 10/2009 - 01/2003

Drug/Important Bio-Agent (IBA)

30	Proteins (Proteins, Gene)FDA Link 05/2022 - 03/2002
27	CytokinesIBA 04/2022 - 03/2000
18	SphingolipidsIBA 09/2021 - 01/2006
17	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 05/2022 - 12/2005
15	sphingosine kinaseIBA 04/2021 - 12/2005
14	Messenger RNA (mRNA)IBA 05/2022 - 01/2003
13	Fingolimod Hydrochloride (FTY720)FDA Link 01/2021 - 11/2009
13	Interleukin-22 (IL-22)IBA 01/2020 - 06/2007
11	EnzymesIBA 01/2019 - 12/2003
11	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2017 - 08/2002
11	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2017 - 03/2000
10	CeramidesIBA 01/2021 - 10/2002
10	SphingosineIBA 01/2019 - 01/2006
10	Interleukin-18 (Interleukin 18)IBA 03/2018 - 08/2003
9	InterleukinsIBA 01/2020 - 08/2002
8	LyasesIBA 10/2020 - 01/2013
8	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020 - 03/2000
8	Nitric Oxide Synthase (NO Synthase)IBA 01/2018 - 03/2002
7	Biomarkers (Surrogate Marker)IBA 01/2021 - 07/2014
7	LipidsIBA 02/2020 - 10/2005
7	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2017 - 03/2000
6	Sphingosine-1-Phosphate ReceptorsIBA 01/2021 - 03/2011
6	Pharmaceutical PreparationsIBA 01/2021 - 08/2002
6	Carrier Proteins (Binding Protein)IBA 12/2019 - 05/2011
6	LipopolysaccharidesIBA 01/2018 - 12/2003
6	Dinoprostone (PGE2)FDA Link 02/2017 - 05/2003
6	Small Interfering RNA (siRNA)IBA 05/2011 - 04/2008
6	LeptinIBA 03/2006 - 04/2003
5	Phosphotransferases (Kinase)IBA 02/2020 - 03/2006
5	InterferonsIBA 01/2020 - 04/2004
5	BiglycanIBA 01/2019 - 07/2003
5	Transforming Growth Factor beta (TGF-beta)IBA 03/2010 - 08/2008
4	Caspase 2IBA 04/2022 - 01/2017
4	Peptide Hydrolases (Proteases)FDA Link 04/2022 - 02/2007
4	nephrinIBA 01/2021 - 05/2003
4	CystathionineIBA 10/2020 - 10/2015
4	ChemokinesIBA 03/2014 - 04/2004
4	Metalloproteases (Metalloproteinases)IBA 02/2013 - 03/2010
4	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 07/2012 - 05/2003
4	p38 Mitogen-Activated Protein KinasesIBA 09/2010 - 02/2007
4	Insulin (Novolin)FDA Link 03/2009 - 03/2006
4	Interleukin-8 (Interleukin 8)IBA 09/2008 - 08/2002
3	Streptozocin (Streptozotocin)FDA Link 01/2021 - 10/2009
3	ceramide kinaseIBA 02/2020 - 01/2014
3	Antiviral Agents (Antivirals)IBA 11/2019 - 03/2015
3	AntigensIBA 01/2019 - 01/2016
3	Acetaminophen (Paracetamol)FDA LinkGeneric 01/2018 - 02/2015
3	Glucose (Dextrose)FDA LinkGeneric 01/2018 - 01/2003
3	Oxygen (Dioxygen)IBA 01/2018 - 10/2005
3	Protein Isoforms (Isoforms)IBA 01/2018 - 05/2003
3	Cyclooxygenase 1IBA 02/2017 - 05/2003
3	CholesterolIBA 01/2017 - 07/2014
3	anti-Thy antibodyIBA 01/2017 - 07/2005
3	Warfarin (Coumadin)FDA LinkGeneric 05/2012 - 01/2011
3	Interleukin-6 (Interleukin 6)IBA 06/2011 - 06/2006
3	Interleukin-10 (Interleukin 10)IBA 10/2010 - 06/2007
3	NF-kappa B (NF-kB)IBA 09/2010 - 02/2004
3	Secretory Phospholipases A2IBA 09/2007 - 01/2005

Therapy/Procedure

16	Therapeutics 12/2019 - 11/2005
3	Drug Therapy (Chemotherapy) 01/2016 - 12/2014